DAY 1 | 18th December 2021 | Saturday
Time	Session Type	Speaker	Session Moderator	Title of Presentation
	Welcome Address by Hon. President of The Sri Lanka Collage of Oncologists
11:00 - 11:30	Session 1 - Breast Cancer - Metastatic
11:00 - 11:10	Presentation	Dr. Cosphiadi Irawan	Dr. Jayantha Balawardane	Trastuzumab plus endocrine therapy or chemotherapy as first - line treatment for metastatic breast cancer with hormone receptor - positive and HER2 - positive: The sysucc - 002 randomized clinical trial.
11:10 - 11:20	Presentation	Dr. Binghe Xu		Dalpiciclib versus placebo plus fulvestrant in HR+/HER2 - advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA - 1): A multicenter, randomized, phase 3 study.
11:20 - 11:30	Presentation	Ms. Anne L Loeser		Treatment - related side effects and views about dosage assessment to sustain quality of life: Results of an advocate - led survey of patients with metastatic breast cancer (MBC).
Quick Quiz Question
11:30 - 12:30	Session 2 - Breast Cancer - Local/Regional/Adjuvant
11:30 - 11:40	Presentation	Dr. Tiromi Menaka Rupasinghe	Dr. Niroshan Atulugama	OlympiA: A phase 3, multicenter, randomized, placebo - controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high - risk HER2 - negative early breast cancer.
11:40 - 11:50	Presentation	Dr. Josephine Lopes Cardozo		Outcome of patients with an ultralow risk 70 - gene signature in the MINDACT trial.
11:50 - 12:00	Presentation	Dr. Ahamed Iqbal		Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B - 42.
12:00 - 12:10	Presentation	Dr. Vaishnavi		De - escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR - /HER2+ early breast cancer: ADAPT - HR - /HER2+ biomarker and survival results.
12:10 - 12:30	Panel Discussion & Q&A Session
12:30 - 12:50	Exhibition Tour Break
12:50 - 13:10	Session 3 - Central Nervous System Tumors
12:50 - 13:00	Presentation	Dr. Buddhini Karunaratne	Dr. Janaka Piyasiri	Long - term results of the GEINO 140 TRIAL: randomizing patients to stop or to continue temozolomide until 12 cycles.
13:00 - 13:10	Presentation	Dr. Ravindi Miriam		Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.
13:10 - 14:20	Session 4 - Heamatology
13:10 - 13:20	Presentation	Dr. Nilupulee Gunarathna	Dr. Yasintha Ratnayake	Safety and efficacy of a novel anti - CD20/CD19 bi - specific CAR T - cell therapy (C - CAR039) in relapsed or refractory (r/r) B - cell non - Hodgkin lymphoma (B - NHL)
13:20 - 13:30	Presentation	Dr. Pradeep Siriwardana		Phase 2 results of the ZUMA - 3 study evaluating KTE - X19, an anti - CD19 chimeric antigen receptor (CAR) T - cell therapy, in adult patients (pts) with relapsed/refractory B - cell acute lymphoblastic leukemia (R/R B - ALL).
13:30 - 13:40	Presentation	Dr. P. W. Devinda C. Jayathilake		CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL)
13:40 - 13:50	Presentation	Dr. Buddhika Somawardana		Upfront autologous stem cell transplantation (ASCT) versus carfilzomib - cyclophosphamide - dexamethasone (KCd) consolidation with K maintenance in transplant - eligible, newly diagnosed (NDTE) multiple myeloma(MM).
13:50 - 14:00	Presentation	Dr. K. A. I. Nirmali Karasinghearachchi		MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue - agnostic cohort of patients with HER2 - positive advanced solid tumors
14:00 - 14:20	Panel Discussion & Q&A Session
14:20 - 15:20	Session 5 - Gastrointestinal & Hepatobiliary Cancer
14:20 - 14:30	Presentation	Dr. Wulyo Rajabto	Dr. Sanjeeva Gunasekara	Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first - line treatment: Results from the randomized FOCUS4 - N trial.
14:30 - 14:40	Presentation	Dr. Chinthaka Appuhamy		Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC - 1 study).
14:40 - 14:50	Presentation	Dr. Kavitha Indranath		Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability - high/mismatch repair deficient metastatic colorectal cancer.
14:50 - 15:00	Presentation	Dr. Chamila Priyadarshani		Trastuzumab deruxtecan (T - DXd; DS - 8201) in patients (pts) with HER2 - expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open - label study (DESTINY - CRC01).
15:00 - 15:20	Panel Discussion & Q&A Session
Quick Quiz Question
15:20 - 15:40	Exhibition Tour Break
15:40 - 16:00	Session 6 - Gyneacologic Cancer
15:40 - 15:50	Presentation	Dr. Hafizah Zaharah	Dr. Lakshan Abeynayake	Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open - label randomized 2 - arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO - OVAR 17/BOOST, GINECO OV118, ENGOT Ov - 15, NCT01462890).
15:50 - 16:00	Presentation	Dr. Linda R. Mileshkin		Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).
16:00 - 17:00	Session 7 - Genitourinary Cancer - Prostate, Testicular and Penile (Dr. N.Jeyakumaran)
16:00 - 16:10	Presentation	Dr. Nisha Shariff	Dr. N. Jeyakumaran	Final analysis of KEYNOTE - 426: Pembrolizumab plus axitinib versus sunitinib as first - line therapy for advanced clear cell renal cell carcinoma (ccRCC).
16:10 - 16:20	Presentation	Dr. Jaliya Jayasekara		A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration - sensitive prostate cancer (mCSPC): First results of PEACE - 1.
16:20 - 16:30	Presentation	Dr. Nuradh Joseph		Phase 3 study of lutetium - 177 - PSMA - 617 in patients within metastatic castration - resistant prostate cancer(VISION).
16:30 - 16:40	Presentation	Dr. Toni K. Choueiri		Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double - blind, phase 3 KEYNOTE - 564 study.
16:40 - 17:00	Panel Discussion & Q&A Session
DAY 2 | 19th December 2021 | Sunday
Time	Session Type	Speaker	Session Moderator	Title of Presentation
	Opening Remarks by Secretary of The Sri Lanka Collage of Oncologists
11:00 - 11:20	Session 8 – Head and Neck
11:00 - 11:10	Presentation	Dr. Andhika	Dr. Kanthi Perera	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
11:10 - 11:20	Presentation	Dr. Tan Chih Kiang		JUPITER - 02: Randomized,double - blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first - line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Quick Quiz Question
11:20 - 11:40	Session 9 – Melanoma/ Sarcoma
11:20 - 11:30	Presentation	Dr. Yasiru Malinda	Dr. N. Yoganathan	CheckMate 067: 6.5 - year outcomes in patients (pts) with advanced melanoma.
11:30 - 11:40	Presentation	Dr. Dimosthenis Andreou		Treatment delays are associated with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro - E.W.I.N.G.99 trial.
Quick Quiz Question
11:40 - 12:00	Exhibition Tour Break
12:00 - 13:00	Session 10 – Lung Cancer
12:00 - 12:10	Presentation	Dr. Dhammike Rasnayake	Dr. Praveen Tharanga	Video - assisted thoracoscopic versus open lobectomy in patients with early - stage lung cancer: One - year results from a randomized controlled trial (VIOLET).
12:10 - 12:20	Presentation	Dr. Chrishanthi Rajasooriyar		Phase 3 comparison of high - dose once - daily (QD) thoracic radiotherapy (TRT) with standard twice - daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
12:20 - 12:30	Presentation	Dr. Dean A. Fennell		A randomized phase II trial of oral vinorelbine as second - line therapy for patients with malignant pleural mesothelioma
12:30 - 12:40	Presentation	Dr. David Lee		First - line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non - small cell lung cancer (NSCLC): Two - year update from CheckMat9LA.
12:40 - 12:50	Presentation	Dr. Tirusha Nawarathne		Pooled analyses of immune - related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
12:50 - 13:10	Panel Discussion & Q&A Session
13:10 -   14:00	Session 11 – Pediatric Oncology
13:10 - 13:20	Presentation	Dr. Sanjeeva Gunasekara	Dr. Sachini Rasnayakes	Updated outcomes for patients with completely resected pulmonary recurrent osteosarcoma: A report from the Children’s Oncology Group.
13:20 - 13:30	Presentation	Dr. Prabani S.Maddumaarachchi		Prognostic Impact of CNS - 2 status in T - ALL: a report from the Children’s Oncology Group.
13:30 - 13:40	Presentation	Dr. P. H. Sahan Piya Udara		Donor - derived CD7 CAR T cells for T - cell acute lymphoblastic leukemia.
13:40 - 14:00	Panel Discussion & Q&A Session
14:00 - 14:10	Session 12 – Other
14:00 - 14:10	Presentation	Dr. Noorwati Sutandyo	Dr. A. J. Hilmi	The comparative effectiveness of direct oral anti - coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
Quick Quiz Question
14:10 onwards	Award Declaration & Valedictory (Dr. Sachini Rasnayake)